← All trials
NCT06037590
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 25, 2023
- Primary completion
- Oct 20, 2023
- Completion date
- Oct 27, 2023
- First posted
- Sep 14, 2023
- Last posted
- Oct 27, 2023
- Enrollment
- 26
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PureIMS B.V.Lead sponsor
- Cooperative Clinical Drug Research and Development AG (CCDRD AG)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.